Showing 2041-2050 of 2494 results for "".
- Oculus Announces Parnership with Luvo to Offer New IPL and RF Devices for the US Ophthalmic Markethttps://modernod.com/news/oculus-announces-parnership-with-luvo-to-offer-new-ipl-and-rf-devices-for-the-us-ophthalmic-market/2481853/Oculus has announced a strategic partnership with Luvo to bring new specialty care devices to the US optometry and ophthalmology market. As part of the deal, Oculus is launching the Luvo Lucent and Darwin with Intense Pulse Light and Radio Frequency therapy, which are designed to e
- Optometry and Vision Science Names New Editor-in-Chiefhttps://modernod.com/news/optometry-and-vision-science-announces-new-editor-in-chief/2481744/The American Academy of Optometry (AAO) announced that David Elliott, PhD, FCOptom, FAAO, is the new editor-in-chief of Optometry and Vision Science (OVS). Mr. Elliott succeeds Michael Twa, OD, PhD, FAAO, who is stepping down from the role after 7 years.
- Centricity: Study Finds Zepto Precision Pulse Capsulotomy Offers Advantages Over Manual Capsulorhexis in Treating White Cataractshttps://modernod.com/news/centricy-study-finds-zepto-precision-pulse-capsulotomy-offers-advantages-over-manual-capsulorhexis-in-treating-white-cataracts/2481513/Centricity Vision announced that a
- Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi for In-Office Pupil Dilationhttps://modernod.com/news/eyenovia-announces-fda-acceptance-of-new-drug-application-for-mydcombi-for-in-office-pupil-dilation/2481289/Eyenovia announced that the FDA has accepted for review the company’s new drug application (NDA) for MydCombi ophthalmic spray. MydCombi is a drug-device combination product that comprises the company’s proprietary, first-in-class combination of tropicamide and phe
- Topcon Offers Maestro2 OCT Certification Coursehttps://modernod.com/news/topcon-offers-maestro2-oct-certification-course/2481213/Topcon Healthcare has announced the new
- High-Tech Imaging Offers New Way to Detect Signs of Early Glaucomahttps://modernod.com/news/high-tech-imaging-offers-new-way-to-detect-signs-of-early-glaucoma/2481008/A new, noninvasive ocular imaging method may be able to detect an early indicator of glaucoma in time to prevent disease progression and vision loss, according to a new study from New York Eye and Ear Infirmary of Mount Sinai (NYEE). The study was published in the July/August issue of Op
- Prevent Blindness and Aerie Pharmaceuticals Partner to Offer New Glaucoma Research Granthttps://modernod.com/news/prevent-blindness-and-aerie-pharmaceuticals-partner-to-offer-new-glaucoma-research-grant/2480868/Research to Prevent Blindness (RPB) and Aerie Pharmaceuticals are partnering to provide early- to mid-career vision scientists with opportunities to pursue glaucoma research of unusual significance and promise. RPB announced the launch the RPB/David L. Epstein Career Advancem
- Alimera Exhibits Continued Growth and Expansion With New Branding and Office Relocationhttps://modernod.com/news/alimera-exhibits-continued-growth-and-expansion-with-new-branding-and-office-relocation/2480750/Alimera Sciences announced that the company has launched new corporate branding and moved its global headquarters to a new, state-of-the-art facility. Alimera refreshed its corporate brand for the first time in the company’s two-decade history to better represent its current
- Ora Names Gustavo De Moraes, MD, PHD, Chief Medical Officerhttps://modernod.com/news/ora-names-gustavo-de-moraes-md-phd-chief-medical-officer/2480622/Ora announced that distinguished op
- Bausch + Lomb Files Registration Statement for Proposed Initial Public Offeringhttps://modernod.com/news/bausch-lomb-corporation-files-registration-statement-and-preliminary-prospectus-for-proposed-initial-public-offering/2480570/Bausch Health Companies announced that in connection with its previously announced intention to separate its eye health business, its wholly owned subsidiary, Bausch + Lomb, has publicly filed a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission (SE